A Randomized, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rofecoxib in the Treatment of Chronic Nonbacterial Prostatitis

Nickel, J. Curtis; Pontari, Michel A.; Moon, Timothy D.; Gittelman, Marc; Malek, Gholam H.; Farrington, Jean; Pearson, Jay D.; Krupa, David; Bach, Michael K.; Drisko, Jennifer E.; Coles, John G.; Cook, David; Dula, Eugene; Ellis, David; Fallick, Mark L.; Feldman, Robert; Hudson, Perry B.; Israeli, Ron; Jacoby, Karny; Kaplan, Steven A.; Kaufman, Joel M.; McMurray, James G.; Murdock, Myron I.; Neal, Durwood E.; Potts, Jeannette M.; Resnick, Harvey; Roehrborn, Claus G.; Schaeffer, Anthony J.; Tomera, Kevin M.; Zinner, Norman R.

doi:10.1097/01.ju.0000054983.45096.16

Cited by 129 publications

(65 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After the 1st, 2nd, 4th, and 6th weeks of therapy, all patients underwent another physical examination and filled out the NIH-CPSI questionnaire again. In addition, a subjective global assessment (SGA) (12)(13)(14)(15) was completed during the 1st, 2nd, 4th and 6th weeks after the baseline assessment.…”

Section: Methodsmentioning

confidence: 99%

Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA)

Zhao

Zhang

et al. 2009

Braz J Med Biol Res

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA)

Zhao

Zhang

et al. 2009

Braz J Med Biol Res

View full text Add to dashboard Cite

“…Only two RCTs were identified for NSAIDs, one of which evaluated rofecoxib [75] (now withdrawn from the market).…”

Section: Pain Pharmacotherapiesmentioning

confidence: 99%

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Rees

Abrahams

Doble³

et al. 2015

BJU International

241

193

View full text Add to dashboard Cite

ObjectivesTo improve awareness and recognition of chronic bacterial prostatitis (CBP) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) among non-specialists and patients. To provide guidance to healthcare professionals treating patients with CBP and CP/CPPS, in both non-specialist and specialist settings. To promote efficient referral of care between nonspecialists and specialists and the involvement of the multidisciplinary team (MDT). Patients and MethodsThe guideline population were men with CBP or CP/CPPS (persistent or recurrent symptoms and no other urogenital pathology for ≥3 of the previous 6 months). Consensus recommendations for the guidelines were based on a search to identify literature on the diagnosis and management of CBP and CP/CPPS (published between 1999 and February 2014). A Delphi panel process was used where high-quality, published evidence was lacking. ResultsCBP and CP/CPPS can present with a wide range of clinical manifestations. The four main symptom domains are urogenital pain, lower urinary tract symptoms (LUTSvoiding or storage symptoms), psychological issues and sexual dysfunction. Patients should be managed according to their individual symptom pattern. Options for first-line treatment include antibiotics, a-adrenergic antagonists (if voiding LUTS are present) and simple analgesics. Repeated use of antibiotics, such as quinolones, should be avoided if there is no obvious symptomatic benefit from infection control or cultures do not support an infectious cause. Early use of treatments targeting neuropathic pain and/or referral to specialist services should be considered for patients who do not respond to initial measures. An MDT approach (urologists, pain specialists, nurse specialists, specialist physiotherapists, general practitioners, cognitive behavioural therapists/psychologists, and sexual health specialists) is recommended. Patients should be fully informed about the possible underlying causes and treatment options, including an explanation of the chronic pain cycle. ConclusionChronic prostatitis can present with a wide variety of signs and symptoms. Identification of individual symptom patterns and a symptom-based treatment approach are recommended. Further research is required to evaluate management options for CBP and CP/CPPS.

show abstract

“…[16][17][18][19]21,22 The dropout rate for trials ranged from 3% to 21%. Out of a maximum quality score of 5, the mean study quality was 4.6 and the median was 5.…”

Section: Statistical Analysis and Methodologic Qualitymentioning

confidence: 99%

Management of chronic prostatitis/chronic pelvic pain syndrome: An evidence-based approach

Dimitrakov

Kaplan

Kroenke

et al. 2006

Urology

View full text Add to dashboard Cite

A Randomized, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rofecoxib in the Treatment of Chronic Nonbacterial Prostatitis

Cited by 129 publications

References 13 publications

Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA)

Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA)

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Management of chronic prostatitis/chronic pelvic pain syndrome: An evidence-based approach

Contact Info

Product

Resources

About